The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension

Journal of Glaucoma

Volumn 18, Issue 4, 2009, Pages 293-300

  Manni, Gianluca ^a   Denis, Phillipe ^c   Chew, Paul ^d   Sharpe, Elisabeth D ^f   Orengo Nania, Silvia ^g   Coote, Michael A ⁱ   Laganovska, Guna ^j   Volksone, Lasma ^k   Zeyen, Thierry ^l   Filatori, Isabella ^b   James, John ^h   Aung, Tin ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Alcon Italia SpA   (Italy)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^f Glaucoma Consultants and Center for Eye Research   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h ALCON RESEARCH LTD   (United States)

ⁱ Royal Victorian Eye and Ear Hospital   (Australia)

^j PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^k Clinical Hospital Gailezers   (Latvia)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Brinzolamide; Dorzolamide; Fixed combination; Glaucoma; IOP; Timolol

Indexed keywords

ANTIGLAUCOMA AGENT; AZARGA; BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY SENSATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR HYPEREMIA; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; SULFONAMIDES; THIAZINES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651183720     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31818fb434     Document Type: Article

References (33)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90:262-267.
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720; discussion 829-830.
3. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56. (Pubitemid 36401765)
4. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114:1965-1972. (Pubitemid 350016362)
5. European Society Guidelines, Terminology and Guideline for Glaucoma, IIth Edition, 2003.
6. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
7. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120: 1268-1279. (Pubitemid 36105431)
8. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126: 498-505. (Pubitemid 28475913)
9. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12: 393-398.
10. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005; 112:863-868.
11. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-540.
12. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of Travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140: 1.e1-1.e8. (Pubitemid 41008083)
13. De Saint Jean M, Debbash C, Brignole F, et al. Toxicity of preserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94. (Pubitemid 30099159)
14. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15: 132-135. (Pubitemid 38457133)
15. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(suppl 2):S119-S129.
16. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369-1372.
17. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22:1204-1212. (Pubitemid 30809728)
18. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105: 1945-1951.
19. Sacca SC, Rolando M, Marletta A, et al. Fluctuation of intraocular pressure during the day in open angle glaucoma, normal-tension glaucoma and normal subject. Ophthalmologica. 1998;212:115-119. (Pubitemid 28064918)
20. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142. (Pubitemid 32441322)
21. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635. (Pubitemid 39179673)
22. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.
23. Ishibashi T, Mori K, Ikeda Y, et al. Blurred vision alter instillation of brinzolamid enad dorzoamide. Invest Opthalmol Vis Sci. 2004;45(suppl):U451.
24. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther. 2003;25:1172-1185. (Pubitemid 36532585)
25. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606. (Pubitemid 41455298)
26. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17: 190-195.
27. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
28. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
29. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423. (Pubitemid 34293291)
30. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
31. Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543-1548.
32. Azarga [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 2008.
33. Cosopt [package insert]. Whitehouse Station, NJ: Merck and Co Inc; 2006.